Back to top

Harrow: Operational Stabilization and Retina Growth Support Buy Rating with Unchanged $63 Price Target

Analyst Thomas Shrader of BTIG maintained a Buy rating on Harrow Health, retaining the price target of $63.00. Thomas Shrader has given his Buy rat...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Harrow, Inc. (HROW)